&lt;b&gt;&lt;i&gt;BCR-ABL1&lt;/i&gt;&lt;/b&gt;&lt;sup&gt;&lt;i&gt;+&lt;/i&gt;&lt;/sup&gt; Acute Myeloid Leukemia: Clonal Selection of a &lt;b&gt;&lt;i&gt;BCR-ABL1&lt;/i&gt;&lt;/b&gt;&lt;sup&gt;&lt;i&gt;-&lt;/i&gt;&lt;/sup&gt; Subclone as a Cause of Refractory Disease with Nilotinib Treatment

Neuendorff, Nina Rosa; Schwarz, Michaela; Hemmati, Philipp; Türkmen, Seval; Bommer, Christiane; Burmeister, Thomas; Dörken, Bernd; Coutre, Philipp le; Arnold, Renate; Westermann, Jörg

doi:10.1159/000368176

Cited by 13 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One patient achieved a CCyR, but died of a brain abscess, two patients had a transient response [73,76], and two patients had no response [66,75]. Interestingly, in three patients, the TKI treatment led to an eradication of the Ph-positive clone despite an overall refractory disease [65,74,77]. This clearly shows the clonal diversity of BCR-ABL+ AML in contrast to chronic phase CML, which is strictly addicted to BCR-ABL.…”

Section: Treatment Of Bcr-abl+ Amlmentioning

confidence: 88%

See 1 more Smart Citation

BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features

et al. 2016

Self Cite

View full text Add to dashboard Cite

BCR-ABL-positive acute myeloid leukemia (AML) is a rare subtype of AML that is now included as a provisional entity in the 2016 revised WHO classification of myeloid malignancies. Since a clear distinction between de novo BCR-ABL+ AML and chronic myeloid leukemia (CML) blast crisis is challenging in many cases, the existence of de novo BCR-ABL+ AML has been a matter of debate for a long time. However, there is increasing evidence suggesting that BCR-ABL+ AML is in fact a distinct subgroup of AML. In this study, we analyzed all published cases since 1975 as well as cases from our institution in order to present common clinical and molecular features of this rare disease. Our analysis shows that BCR-ABL predominantly occurs in AML-NOS, CBF leukemia, and AML with myelodysplasia-related changes. The most common BCR-ABL transcripts (p190 and p210) are nearly equally distributed. Based on the analysis of published data, we provide a clinical algorithm for the initial differential diagnosis of BCR-ABL+ AML. The prognosis of BCR-ABL+ AML seems to depend on the cytogenetic and/or molecular background rather than on BCR-ABL itself. A therapy with tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, or nilotinib is reasonable, but-due to a lack of systematic clinical data-their use cannot be routinely recommended in first-line therapy. Beyond first-line treatment of AML, the use of TKI remains an individual decision, both in combination with intensive chemotherapy and/or as a bridge to allogeneic stem cell transplantation. In each single case, potential benefits have to be weighed against potential risks.

show abstract

Section: Treatment Of Bcr-abl+ Amlmentioning

confidence: 88%

“…In 14 published cases, BCR-ABL was acquired upon AML relapse [11,55,[71][72][73][74][75][76][77]. In 7 of these 14 patients, the morphologic classification was given.…”

Section: ) Bcr-abl At Aml Relapsementioning

confidence: 99%

BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…The appearance of BCR/ABL1 in AML has been described in combination with different class II aberrations such as CBFβ/MYH11, RUNX1/RUNX1T1, PML/RARa, and NPM1. Neuendorff et al [ 17 ] showed a case of BCR/ABL1 + MLL/AF6 + AML without NPM1 aberrations. MLL rearrangements were mostly considered as class II aberrations.…”

Section: Discussionmentioning

confidence: 99%

Primary Philadelphia chromosome positive acute myeloid leukemia

Shao

Chen

et al. 2018

Medicine

View full text Add to dashboard Cite

Rationale:Philadelphia chromosome positive acute myeloid leukemia (Ph+ AML) is a rare subtype of AML that is now included as a provisional entity in the 2016 revised WHO classification of myeloid malignancies. However, a clear distinction between de novo Ph+ AML and chronic myeloid leukemia blast crisis is challenging. It is still a matter of debate whether Ph+ AML patients should be treated with chemotherapy or tyrosine kinase inhibitors as first-line therapy.Patient concerns:We reported here a case of a 46-year-old man who was diagnosed as Ph+ AML. This diagnosis was confirmed by bone marrow pathology and karyotype analysis of 46, XY, t (9; 22). Further examination, molecular genetic analysis showed BCR/ABL1 (p190) without ABL1 kinase domain mutations, and direct evidence demonstrated in AML by flow cytometry.Diagnosis:The diagnosis of Ph+ AML was made on May 2016 according to morphology, immunology, cytogenetic, and molecular criteria, and multiple organ failure was also diagnosed.Interventions:The patient was treated with dasatinib as the only medication after experiencing multiple organ failure. Then, he received 2 cycles of chemotherapy with IA (idarubicin 8 mg/m2, day 1–3; cytarabine 100 mg/m2, day 1–7) in August, 2016.Outcomes:The patient finally achieved a complete molecular remission.Lessons:This case study suggests that dasatinib can be a safe and effective treatment for Ph+ AML patients with poor physical condition.

show abstract

“…Diese Aberration ist damit der diagnostische Marker schlechthin. Sie ist ebenfalls in einem Teil der akuten lymphatischen Leukämien (ALL) des Erwachsenen-und Kindesalters nachweisbar sowie in einem geringen Anteil der akuten myeloischen Leukämien (AML [3][4][5]). …”

Section: Hintergrundunclassified

Detektion der BCR-ABL-Fusion

et al. 2015

View full text Add to dashboard Cite

Chronic myeloid leukemia (CML) is diagnostically defined by the reciprocal translocation t(9;22)(q34;q11). This aberration can be detected by the BCR-ABL fluorescence in situ hybridization (FISH) technique. This article presents a comparative analysis of different commercially available FISH probes and different FISH protocols in order to optimize this technique on formalin-fixed and paraffin-embedded bone marrow trephine biopsies.

show abstract

<b><i>BCR-ABL1</i></b><sup><i>+</i></sup> Acute Myeloid Leukemia: Clonal Selection of a <b><i>BCR-ABL1</i></b><sup><i>-</i></sup> Subclone as a Cause of Refractory Disease with Nilotinib Treatment

Cited by 13 publications

References 17 publications

BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features

BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features

Primary Philadelphia chromosome positive acute myeloid leukemia

Detektion der BCR-ABL-Fusion

Contact Info

Product

Resources

About